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Abstract
Background: Melanoma of the anal region is a very uncommon disease, accounting for only 0.2-0.3% of all
melanoma cases. Mutations of the BRAF gene are usually absent in melanomas occurring in this region as well as
in other sun-protected regions. The development of a tumour in a longstanding perianal fistula is also extremely
rare. More frequent is the case of a tumour presenting as a fistula, that is, the fistula being a consequence of the
cancerous process, although we have found only two cases of fistula-generating melanomas reported in the
literature.
Case Presentation: Here we report the case of a 38-year-old male who presented with a perianal fistula of four
years of evolution. Histopathological examination of the fistulous tract confirmed the presence of malignant
melanoma. Due to the small size and the central location of the melanoma inside the fistulous tract, we believe
the melanoma reported here developed in the epithelium of the fistula once the latter was already formed.
Resected sentinel lymph nodes were negative and the patient, after going through a wide local excision, remains
disease-free nine years after diagnosis. DNA obtained from melanoma tissue was analysed by automated direct
sequencing and the V600E (T1799A) mutation was detected in exon 15 of the BRAF gene.
Conclusion: Since fistulae experience persistent inflammation, the fact that this melanoma harbours a BRAF
mutation strengthens the view that oxidative stress caused by inflammatory processes plays an important role in
the genesis of BRAF gene mutations.
Background
Malignant melanomas of the anal region are a rare
occurrence, accounting for only around 0.2-0.3% of all
melanoma cases and 4% of anal cancers [1]. Diagnosis
may be challenging, since perianal melanomas may be
disguised as haemorrhoids [2] and more rarely as fis-
sures [3] or perianal abscesses [4]. Prognosis is generally
very poor [5], with five-year survival rates ranging
between 6.7% and 16% [6,7].
The BRAF gene encodes a serine/threonine kinase
involved in the mitogen-activated protein kinase path-
way (MAPK) [8]. Activating BRAF mutations are present
in approximately 70% of cutaneous malignant
melanomas [9] and 82% of melanocytic naevi [10]. More
than 90% of BRAF mutations involve a single point
mutation, T1799A, in codon 600 of exon 15, leading to
a V600E amino acid substitution [9,10]. However, sev-
eral studies have shown that BRAF mutations are very
uncommon in melanomas arising in sun-protected areas
[11-13]. These findings have suggested an association
b e t w e e nt h ep r e s e n c eo fBRAF mutations in malignant
melanomas and ultraviolet (UV) light exposure.
In this report we describe a case of malignant mela-
noma presenting in a perianal fistula. To the authors’
knowledge, this clinical presentation has not been pre-
viously described in the scientific literature. To add to
our knowledge of this rare entity, we have determined
the mutational status of the BRAF gene in tumour tissue
of the patient.
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The patient was a 38-year-old male with a history of beta-
thalassaemia minor with pseudopolycythemia and micro-
cytosis. In May 2002 he underwent surgery for a perianal
fistula of four years of evolution. Pathologic examination
of the resected specimen revealed an abscessed fistulous
tract with the presence of a small core of hyperpigmented
and hyperplastic basal melanocytes arranged irregularly
and forming a lentiginous pattern (Figure 1). A nest of
epithelioid cells with atypical anaplastic nuclei, prominent
nucleoli and abundant melanin was clearly discernible in
the underlying dermis (Figure 1). Besides, features rela-
tively specific for melanoma including absence of matura-
tion and presence of mitoses in deep cells were also visible
(Figure 1). Finally, other secondary characteristic also sug-
gestive of melanoma was the abundant melanic pigment
throughout the lesion, both in the depth of the lesion and
in the upper portion of the epidermis, including the stra-
tum corneum or horny layer of the epidermis.
In June 2002, once the diagnosis of melanoma in peri-
anal fistula (Clark level III) had been confirmed by the
pathologist, the patient went through a surgical exten-
sion of excision margins (1 cm) and a sentinel lymph
node biopsy (one right and two left inguinal nodes).
Both the extended margins and the sentinel lymph
nodes produced negative results for tumour cells.
In order to discard the possibility of metastatic mela-
noma, the patient was also subjected to an abdominal
ultrasound examination and a whole body CT scan,
both without relevant findings. Serum levels of S-100
protein, a widely used melanoma marker, were also
negative. The patient went through his latest follow-up
in December 2010, and at the time of this report he
remains free of disease.
Methods
DNA extraction
Five μm sections from tumour tissue were stained with a
standard Haematoxylin-Eosin protocol. Histological slides
were examined with a Leica DM2000 microscope and
micrographs were taken using a Leica DMD108 microima-
ging device with integrated camera (Leica Microsystems,
Wetzlar, Germany). Slides were then cleaned with 99%
ethanol for 15 minutes and left to air-dry overnight. Mela-
noma tissue was then manually dissected from surround-
ing normal tissue with a sterile blade. DNA extraction
from dissected melanoma tissue was performed using the
ChargeSwitch gDNA Tissue Kit (Invitrogen, Carlsbad,
USA) according to the manufacturer’si n s t r u c t i o n s .
Detection of the V600E mutation
Melanoma DNA, a control sample (from peripheral blood
of the same patient) and DNA extracted from melanoma
cell line A375 were analysed for the V600E mutation at
nucleotide 1799 of the BRAF gene by direct automated
DNA sequencing. PCR primer sequences used to amplify
a 102-bp fragment containing nucleotide 1799 of exon 15
Figure 1 Photomicrographic images of the fistula melanoma.
A) Fistulous tract course with nest of melanocytic cells
(Haematoxylin-Eosin staining; magnification 4×). B) Closer view of
the melanocytic cell core (H&E; magnification 10×). C) Melanoma
cancerous cells, including one undergoing mitosis (H&E;
magnification 40×).
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Page 2 of 6were: 5’-GAAGACCTCACAGTAAAAATAGG TGA-3’
(sense) and 5’-CCACAAAATGGATCCAGACA-3’ (anti-
sense). PCR reactions were carried out using about 100 ng
of melanoma DNA as template. Thermocycling conditions
included a denaturation step at 95°C for 8 minutes, fol-
lowed by 40 cycles of 95°C for 30 seconds, 56°C for 45 sec-
onds and 72°C for 1 minute, plus a final extension cycle of
72°C for 10 minutes. Amplified products were purified
using ExoSAP-IT (USB Corporation, Cleveland, USA)
according to the manufacturer’s instructions. Purified PCR
products were then run on an ABI 3130 Genetic Analyzer
(Applied Biosystems, Foster City, USA) and analysed using
software supplied by the manufacturer.
All new sequence data contained in this study has
been deposited in the GenBank sequence database [Gen-
Bank:HQ224878].
Appropriate ethical approval for this research was
obtained from the Ethics and Clinical Research Commit-
tee (CEIC) of the Castellon Province Hospital. Written
informed consent was obtained from the patient for the
study and its reportings.
Results
High quality sequencing was obtained in both the 5’ and
the 3’ direction from the melanoma sample, the control
DNA sample and melanoma cell line A375. The V600E
mutation (T1799A)i ne x o n1 5o ft h eBRAF gene was
present in the heterozygous state in the melanoma sam-
ple, but it was absent in non-tumour DNA obtained
from peripheral blood of the same melanoma patient
(Figure 2). As expected, the positive control sample,
melanoma cell line A375, showed the V600E mutation
in the homozygous state (Figure 2).
Discussion
The development of a tumour inside a longstanding fis-
tula is an extremely infrequent event. More frequent is
the case of a tumour presenting as a fistula, that is, the
fistula being a consequence of the cancerous process.
Occasionally, the inflammation and necrosis caused by
the development and progression of a tumour stimulates
the formation of a fistula. However, there are instances
in which the fistula is not a secondary manifestation of
the neoplasia, and its formation predates the develop-
ment of the tumour. In these cases, the neoplastic trans-
formation arises inside the longstanding fistula, probably
due to the latter’s chronic inflammatory nature [14]. We
have found several cases in the literature in which a
variety of different tumour types have developed inside
a fistula once the latter was already formed, such as
squamous cell carcinomas [15-17], basal cell carcinomas
[18,19] and mucinous adenocarcinomas [17,20-22].
As far as the authors are aware, the occurrence of a
melanoma within a fistula has not been previously
described in the literature. We have found two pub-
lished cases of melanomas presenting with fistulous for-
mations, one concerning a biliary tract fistula [23] and
another one presenting as a urethral fistula [24], in
which the appearances of the fistulas were a conse-
quence of the cancerous process.
In our patient, the fistula melanoma was quite small
(Figure 1) and it was found by chance while the pathol-
ogist examined the stained histological sections of the
Figure 2 Sequence chromatograms of the negative control, the
fistula melanoma and the positive control DNA samples.A )
DNA from peripheral blood of the fistula melanoma patient with an
arrow showing the wild-type genotype (the T allele in
homozygosis). B) DNA from the perianal fistula melanoma showing
the T1799A mutation in heterozygosis (arrow). C) DNA from
melanoma cell line A375, with the mutation in the homozygous
state.
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subcutaneous tissue, next to the fistulous tract, the
interior of which was already epithelialised. It was sur-
rounded by abundant inflammatory response and next
to a lesion showing atypical lentiginous melanocytic
hyperplasia (Figure 3). The presence of lentiginous
hyperplasia suggested that the melanocytic lesion origi-
nated inside the fistulous tract and that we were indeed
in front of a primary melanoma and not a metastasis
(already ruled out by the whole body CT scan). On the
other hand, the opening of the fistulous tract in the
perianal skin epidermis did not contain signs of inflam-
mation or malignant tissue (Figure 3), which ruled out
the possibility of the fistula being a complication or a
secondary manifestation of a cutaneous melanoma [14].
Therefore, we believe that the fistula predated the mela-
noma, not the other way around, and that it arose as a
complication of the inflammatory lesion of the fistula.
Anal melanoma is an uncommon disease that affects
patients of advanced age, usually appearing in the sixth
or seventh decade of life [25,26]. However, Cagir and
cols. found an increased incidence of anorectal melano-
mas in males aged 25 to 44 years living in the San Fran-
c i s c oa r e a[ 2 7 ] ,a n dt h e yp r o p o s e dH I Vi n f e c t i o na sa
risk factor for anorectal melanoma. But the HIV test in
our patient (who was 38 years of age at diagnosis) was
negative, and he had neither a previous history nor
signs of other sexually-transmitted diseases.
T h ef a c tt h a tt h i sm e l a n o m ao r i g i n a t e di nap e r i a n a l
location and inside a fistula also ruled out UV light
exposure as a possible aetiological factor. Classic genetic
mutations caused by UV exposure comprise C>T and
CC>TT transitions, although UV exposure generates
oxygen-free radicals that also damage DNA and give
rise to other types of base substitutions [28]. Even
though BRAF mutations occur more frequently in mela-
nomas linked to sun exposure, the BRAF gene does not
contain C>T or CC>TT transitions typical of UV-
induced damage. The commonest BRAF mutation by far
is T1799A (V600E), a T>A transversion present in more
than 90% of all BRAF-mutated melanomas and naevi.
Due to the detection of the V600E BRAF mutation in
this fistula melanoma, it was decided not to look for
alterations in genes such as CCND1 or KIT,m o r ef r e -
quently mutated in acral and mucosal melanomas [29],
since concomitant mutations in BRAF and in genes
such as KIT or CCND1 are extremely rare [29]. Regard-
ing this, it has to be understood that, although this mel-
anoma arose in the perianal region, it was not a case of
mucosal melanoma, since it did not originate in the anal
mucous membrane of the patient.
BRAF mutations, including T1799A, have occasionally
been found in anal mucosal melanomas [30] and in
other tumours not associated with UV exposure [9],
such as thyroid cancer [31,32], colorectal cancer [33-35],
pancreatic cancer [36,37] or ovarian cancer [38,39]. The
development of all these tumour types may, in turn, be
related to inflammatory processes [12], in the same way
as cutaneous melanoma is associated with inflammation
of the skin caused by UV exposure [40]. Accordingly,
oxidative stress caused by inflammation may be in part
responsible for mutations in the BRAF gene [12]. Since
fistulae are environments that experience permanent
inflammatory processes, the fact that the fistula mela-
noma reported here is carrying the T1799A transversion
supports the hypothesis that oxidative damage caused
by free radicals plays a role in the genesis of BRAF
mutations.
Obviously, we are not presuming that all inflammation
must cause BRAF mutations, but that persistent or
chronic inflammatory processes in the absence of UV
exposure (such as thyroiditis in thyroid cancer [31],
chronic pancreatitis in pancreatic cancer [37], chronic
bowel inflammation in colon cancer [41] and, in our
case, a longstanding fistula in a melanoma), can prob-
ably make the BRAF gene more susceptible to genetic
mutations via an as yet unidentified oxidative stress
lesion.
As to the management of the perianal fistula mela-
noma, this case illustrates the benefits provided by the
use of sentinel lymph node biopsy. Similarly to anorectal
melanoma cases [42], the sentinel lymph nodes were
l o c a t e di nt h eg r o i n ,n o ti nt h ep r e s a c r a lr e g i o n .A s
mentioned above, all three nodes dissected were free of
tumour cells. After ruling out abdominoperineal resec-
tion [43], wide local excision (WLE) appears to obtain
Figure 3 Photomicrographic image of a cross-section of the
entire resected fistula piece. This picture of the entire resected
piece (H&E; magnification 2×) shows the fistulous tract, the
lentiginous melanocytic hyperplasia, and the perianal skin epidermis.
Note that the lesion is located in the depth of fistula, not in the
perianal epidermis.
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of choice in melanomas of the anal region [5,26]. Our
case can only corroborate this, since nine years after
WLE our patient remains healthy and without signs of
relapse.
Conclusions
The fact that the melanoma described in this report
a r o s ei n s i d eaf i s t u l am a ys e ti ta p a r tf r o mo t h e ra n a l
and perianal melanomas, as well as from mucosal mela-
nomas in general. In our opinion, and due to the symp-
toms occasioned by the presence of the fistula, this
melanoma was caught at a very early stage compared to
other anorectal or perianal melanomas. The presence of
a BRAF mutation, usually absent in other anal melano-
mas, also suggests different aetiological factors contri-
buting to the development of this particular melanoma,
with inflammatory processes and oxidative stress
damage being possibly among them.
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